VJTBio's mammalian cell-based protein expression platform is an engineered system for producing recombinant proteins with complex post-translational modifications, which are critical for therapeutic and research applications. Utilizing mammalian host cells such as CHO cells, this platform employs specialized plasmids for gene transfection and operates in optimized bioreactors for scalable production. The process involves transfection, culture in optimized media, protein production, and rigorous purification to ensure high yield and quality. This platform is vital for producing therapeutic proteins, monoclonal antibodies, and other biologics with the required biological activity and stability for medical use.

VJTBio's antibody development platform is a comprehensive system that encompasses all stages of therapeutic antibody creation, from initial discovery through clinical production. This platform integrates target identification, antigen preparation, and advanced screening technologies like phage display and hybridoma to discover high-affinity candidates. It includes optimization techniques such as affinity maturation and caninization/felinization to enhance binding specificity and reduce immunogenicity. This platform also integrates rigorous in vitro and in vivo testing for efficacy and safety, and engineering processes that improve stability, expression, purity, and manufacturability.

Pilot production platform is the key to CMC and to ensure the stability of the drug batch. VJTBio has established the most advanced pilot test and production platform of animal protein drugs in China.